BioDelivery Sciences International closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day. This move lagged the S&P 500's daily loss of 0.46%. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq lost 0.63%.
Heading into today, shares of the specialty pharmaceutical company had gained 5.54% over the past month, outpacing the Medical sector's gain of 0.39% and the S&P 500's gain of 1.08% in that time.
Investors will be hoping for strength from BDSI as it approaches its next earnings release. In that report, analysts expect BDSI to post earnings of -$0.08 per share. This would mark year-over-year growth of 55.56%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $19.49 million, up 72.79% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.19 per share and revenue of $92.05 million. These totals would mark changes of +73.97% and +65.43%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for BDSI. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 13.64% higher. BDSI is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BDSI in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
BioDelivery Sciences International closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day. This move lagged the S&P 500's daily loss of 0.46%. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq lost 0.63%.
Heading into today, shares of the specialty pharmaceutical company had gained 5.54% over the past month, outpacing the Medical sector's gain of 0.39% and the S&P 500's gain of 1.08% in that time.
Investors will be hoping for strength from BDSI as it approaches its next earnings release. In that report, analysts expect BDSI to post earnings of -$0.08 per share. This would mark year-over-year growth of 55.56%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $19.49 million, up 72.79% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.19 per share and revenue of $92.05 million. These totals would mark changes of +73.97% and +65.43%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for BDSI. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 13.64% higher. BDSI is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BDSI in the coming trading sessions, be sure to utilize Zacks.com.